A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

This trial is testing HLX43 — a new drug that delivers chemotherapy directly to cancer cells by attaching to PD-L1, a protein overexpressed in many cancers — in women with advanced gynecological cancers including cervical cancer and ovarian cancer that have progressed after standard treatment. **You may be eligible if...** - You are between 18 and 75 years old - For Cohort 1: You have metastatic or recurrent cervical cancer (squamous, adenocarcinoma, or adenosquamous type) that has progressed on or after standard therapy including platinum-based chemotherapy and immunotherapy (if PD-L1 positive) - For Cohort 2: You have confirmed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer that has progressed after platinum-based therapy - Your cancer has progressed on or after standard treatment **You may NOT be eligible if...** - Your organ function is inadequate to tolerate this treatment - You have active brain metastases or uncontrolled systemic illness - You have had severe prior reactions to similar antibody-drug conjugate therapy - You have serious autoimmune conditions Talk to your doctor to see if this trial is right for you.